Company:  ALDEYRA THERAPEUTICS, INC ... (ALDX)
Form Type:  8-K
Filing Date:  1/14/2020 
CIK:  0001341235 
Address:  131 HARTWELL AVENUE
SUITE 320
 
City, State, Zip:  LEXINGTON, Massachusetts 02421 
Telephone:  781-761-4904 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.98  
Change: 
-0.07 (-1.39%)  
Trade Time: 
Jun 02  
Market Cap: 
$148.36M
Trade ALDX now with 

© 2020  
Description of Business
We are a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Our lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease ("DED") and allergic conjunctivitis ("AC"). We have additional product candidates in development for proliferative vitreoretinopathy ("PVR") and other retinal diseases, autoimmune disease, and cancer. We currently intend to commercialize our products directly or through collaborations. None of our product candidates have been approved for sale in the United States or elsewhere. Immune-mediated diseases are conditions that result from an imbalance of inhibitory and stimulatory factors that regulate the immune system. Immunological dysregulation can lead to a broad array of conditions that include autoimmune disease, allergy, immunoproliferative disease, and cancer.
Register and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02. Departure of Directors or Certain Officers; ...
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1